Attovia Therapeutics Launches with $60 Million Series A Financing to Unlock Potential of Novel Biparatopic Nanobody Platform

Company Formed by Alamar Biosciences and Frazier Life Sciences Attobody™ Platform Generates Small Format Binders for Hard-to-drug Targets FREMONT, Calif. and MENLO PARK, Calif., June 20, 2023 (GLOBE NEWSWIRE) — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, announced the launch of Attovia Therapeutics, a […]

Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer

Proprietary ROVEr™ platform enables design of next-generation radiopharmaceuticals with tunable pharmacokinetic (PK) properties to maximize therapeutic effect and mitigate systemic toxicities Potential for alpha- or beta-emitting radiopharmaceuticals, for clinically validated and novel cancer targets with a wide range of antigen expression Lead program targeting DLL3 for small cell lung cancer and other solid tumors advancing […]

Abdera skyrockets out of stealth with $142M as radiopharmaceutical ambitions take flight

The nature of Abdera Therapeutics’ platform has elevated expectations that Big Pharma will be queuing up to launch licensing opportunities. Lori Lyons-Williams has always been drawn to working in oncology. For the former Allergan leader and Neumora president, there are few opportunities more impactful than treating cancer—and tough-to-target solid tumors at that.  So when given the […]

ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in the ASPEN-07 study evaluating evorpacept, a next generation CD47 blocker, in combination with PADCEV® (enfortumab vedotin-ejfv), […]

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants, including the exercise in full by the underwriters of their option to purchase an additional 833,333 shares. The […]

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

ZUG, Switzerland, Feb. 24, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced a poster detailing positive data from its Phase 2 RAPIDe-1 study of PHVS416 for the on-demand treatment of attacks will be presented at the American Academy […]

Impel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity

Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 Percent Company will Continue to Drive Trudhesa Growth Via 90 Field-Based Sales Representatives and Other Commercial Efforts Trudhesa Growth Momentum Continues, with 58 Percent Increase in New Prescriptions from Q2 2022 to Q4 2022 Following Expansion of Sales Force SEATTLE, Feb. 22, 2023 (GLOBE NEWSWIRE) — […]

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to 8 new employees with a grant date of February 1, 2023, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan […]